Please fill in the form with your username, your password will be send to your registered e-mail.
* Mandatory fields
Website dedicated to help patients, their family and friends about the cancer immunotherapeutic approach in an easy-to-understand format.
Website providing information about the now recruiting Non-Small Cell Lung Cancer phase III clinical study
This section describes the antigens used in ASCI. They have been selected from a range of tumor antigens that are recognized by T lymphocytes.
GSK first focused on MAGE-A3, a genuine tumor-specific antigen that is expressed by several tumor types.
MAGE-A3 is the first antigen entering a Phase III study, the MAGRIT (MAGE-A3 as Adjuvant Non-Small Cell Lung Cancer Immunotherapy) trial.
If this is your first time at this site, please click here to register.
Register now
For legal reasons, this page is intended solely for healthcare professionals. This is why we ask you to register.
© 2001 - 2008 GlaxoSmithKline plc. All rights reserved.